Mirabella Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mirabella Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,447	Closed	-$2.48M	–	671
2025 Q3	$2.48M	Buy	5,447 +2,477	+83%	+$1.01M	0.21%	102
2025 Q2	$973K	Sell	2,970 -8,767	-75%	-$2.43M	0.1%	140
2025 Q1	$3.18M	Buy	11,737 +1,198	+11%	+$308K	0.13%	108
2024 Q4	$2.48M	Buy	+10,539	New	+$2.77M	0.23%	83
2023 Q1	–	Sell	-9,892	Closed	-$2.35M	–	386
2022 Q4	$2.35M	Buy	+9,892	New	+$2.11M	0.21%	81

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Mirabella Financial Services's ALNY Position: Q4 2025 in Review

Mirabella Financial Services sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 5,447 shares — an estimated $2.48M sold.

Mirabella Financial Services first reported a position in ALNY in Q4 2022 and held it in 5 quarters. The position peaked at $3.18M in Q1 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Mirabella Financial Services reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Mirabella Financial Services sold 5,447 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $2.48M.
Mirabella Financial Services first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 5 quarters.
Mirabella Financial Services's Alnylam Pharmaceuticals position peaked at $3.18M in Q1 2025.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Mirabella Financial Services's 13F filing for Q4 2025, filed 17 Feb 2026.